AlphAIAlphAI — Financial news for AI agents
app.dealroom.coAUG 222 min read$HCA

HCA Healthcare beats estimates with $20.23B in quarterly revenue

HCA Healthcare reported Q2 2026 revenue of $20.23B, beating estimates. Earnings were $7.59 per share, up from $6.84 in the same quarter last year. Westpac acquired a new stake worth $4.648M. The company declared a $0.78 quarterly dividend. Analysts have mixed views on the stock, with a Moderate Buy consensus and an average price target of $462.64.

Original reporting
app.dealroom.co
Published Aug 22, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 6:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HCA Healthcare beats estimates with $20.23B in quarterly revenue — source image
Source · app.dealroom.co
Decision brief

The 30-second read

$HCABullishHigh
01

Why it matters

Earnings beat may trigger short-term buying pressure and influence sector ETFs.

02

Market read

Strong earnings could boost HCA stock and positively affect healthcare sector sentiment.

03

What to watch

Dividend yield is low at 0.7%, and institutional ownership is high, possibly limiting upside.

Relevance 9/10Novelty 9/10Timing: post-earnings release

Background

HCA Healthcare is a leading U.S. hospital operator; its quarterly results are closely watched.

Company-level read

Ticker impact

$HCABullishHigh confidence
Context

HCA Healthcare reported Q2 2026 revenue of $20.23B and EPS $7.59, beating estimates.

Expected impact

Potential 2-4% upside in the next trading session.

Evidence & confidence

Revenue beat of 8.7% YoY and EPS beat, combined with a modest dividend, indicate robust performance.

Market effects

Sector

Positive earnings may lift the healthcare services sector.

Regional

U.S. hospital operators could see modest gains.

Global

Limited to U.S. healthcare equities.

Counterpoint

What could challenge this read

Analyst price targets were cut, suggesting potential overvaluation despite beat.

Key entities

  • Analyst
    UBS

    Reduced price target to $579.

  • Analyst
    Mizuho

    Reduced price target to $475.

Read at source← All news

Related articles

SEP 15
$HCAMed

HCA Healthcare Completes CHCP Acquisition; Expands Healthcare Education

HCA Healthcare (HCA) completed its acquisition of The College of Health Care Professions (CHCP), expanding its healthcare education offerings. CHCP serves 8,000 students across 10 Texas campuses and online, with 20 accredited programs. HCA plans to integrate CHCP into its education and workforce development efforts. HCA stock is currently trading at $422.90, down 0.61%.

rttnews.com1 min
SEP 6
$HCAHighAI 8/10

Why Everyone Is Watching HCA Healthcare (HCA) Today

HCA Healthcare (HCA) reduced its 2026 profit outlook, citing a weaker payer mix that decreased quarterly revenue by $400 million. A Pomerantz fraud investigation adds scrutiny. Shares fell 3.07% in 7 days, 2.02% in 30 days, despite a 12.09% gain in 90 days and 51.53% over 3 years. Analysts debate its valuation, with a fair value estimate of $458.67, above the recent $405.00 close.

simplywall.st2 min
AUG 22
$HCAMed

Do Wall Street Analysts Like HCA Healthcare Stock?

HCA Healthcare's analyst ratings have shifted to a more bearish stance. JPMorgan reduced its price target to $425, citing a revised financial model. The mean target is $453.45, implying an 11.6% premium, while the highest target is $579, suggesting a 42.5% upside.

yahoo.com1 min